Effect of Febuxostat on Flow Mediated Diameter in hyperuricemia patients with chronic kidney disease 5D.
- Conditions
- hyperuricemia
- Registration Number
- JPRN-UMIN000014787
- Lead Sponsor
- Tsuruta clinic
- Brief Summary
We randomly assigned 53 hemodialysis patients with hyperuricemia to a febuxostat (10mg daily) group and a control group. Flow-mediated dilation increased from 5.3% to 8.9 in the febuxostat group but did not change significantly in the control group. Treatment with febuxostat resulted in a significant decrease in serum UA level and a significant decrease in MDA-LDL compared with baseline, but no significant difference was observed in hsCRP level or blood pressure. No significant differences were observed in the control group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
Patients who take allopurinol, probenecid, bucolome, febuxostat. Patients with history of hypersensitivity to febuxostat. Patients who take mercaptopurine, azathiopurine, pyrazinamide or ethambutol. Patients participant to other clinical trials within recent 4 weeks. Patients judged not to be suitable as a subject by attending doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method